Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of LX22001 versus esomeprazole sodium injection after endoscopic hemostasis for peptic ulcer bleeding
CTR20250723Phase 2Completed
- Sponsor
- Roxin Pharmaceutical
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of LX22001, esomeprazole sodium in Peptic ulcer disease (PUD), sponsored by Roxin Pharmaceutical. Started Mar 2025; status: completed.
02
Drugs
LX22001esomeprazole sodium
03
Conditions
Peptic ulcer disease (PUD)
Beyond the preview
Go deeper on CTR20250723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250723.